Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498670 | 0.90 | NPSR1 (0.76) | NPSR1ALDH1A1SMN1; SMN2CYP2A6LMNA | |
| SCHEMBL2501529 | 0.85 | NPSR1 (0.83) | NPSR1ALDH1A1TP53POLBTDP1 | |
| SCHEMBL10812615 | 0.85 | NPSR1 (0.70) | NPSR1NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL2513419 | 0.80 | NPSR1 (0.64) | NPSR1ALDH1A1TP53SMN1; SMN2KDM4E | |
| SCHEMBL2830170 | 0.77 | NPSR1 (1.00) | NPSR1ALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL31582321 | 0.77 | NPSR1 (1.00) | NPSR1ALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL9807161 | 0.76 | NPSR1 (0.61) | NPSR1NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL2500327 | 0.76 | PTGS2 (0.48) | NPSR1NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL11719116 | 0.75 | NPSR1 (0.57) | NPSR1NPC1RAB9ATP53POLB | |
| SCHEMBL3572832 | 0.74 | CYP2A6 (0.54) | NPSR1ALDH1A1CYP2A6MAP2K4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2370413-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2015-07-09 | — | — | US | disclosed |
| US-8940891-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2370413-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010077275-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | PTGIR, PTGIS, TBXA2R | NPSR1 612/4885NPC1 2403/4885RAB9A 4259/4885 |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | NPSR1 680/4885NPC1 2651/4885RAB9A 3992/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NPSR1 870/4885NPC1 1539/4885RAB9A 3396/4885 |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | NPSR1 680/4885NPC1 2651/4885RAB9A 3992/4885 |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NPSR1 872/4885NPC1 1542/4885RAB9A 3389/4885 |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NPSR1 870/4885NPC1 1539/4885RAB9A 3396/4885 |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | PTGIR, PTGIS, TBXA2R | NPSR1 612/4885NPC1 2403/4885RAB9A 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.